glp-1 concerns Addressing patient about the 'newness' and long-term safety of GLP- 1 receptor agonists: A clinician's guide to counseling Purchasing a GLP-1 without consulting

Semaglutide (Wegovy) FDA-approved for: Chronic weight management Treatment of Metabolic dysfunction-Associated Steatohepatitis (MASH) approved August 2025 FDA-indicated for: Reducing risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease who are obese or overweight Weekly injection Clinical trials show an average weight loss of 1215% of body weight

doi:10.1016/j.nut.2004.04.003 (3) Kraemer WJ, Volek JS, Dunn-Lewis C

Discontinuation of semaglutide and long-term effects on weight and cardiometabolic risk factors

Diagnosis, treatment, and long-term outcomes of late-onset (type III) multiple acyl-CoA dehydrogenase deficiency

The medication isnt used in people who dont have these conditions

Nutrients 2023;15(19):4257